Results 101 to 110 of about 3,314,611 (329)

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

An Inflammation-Centric View of Neurological Disease: Beyond the Neuron [PDF]

open access: yes, 2018
Inflammation is a complex biological response fundamental to how the body deals with injury and infection to eliminate the initial cause of cell injury and effect repair.
Facci, Laura   +3 more
core   +2 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

open access: yesFrontiers in Immunology, 2019
Antibodies and Fc-fusion antibody-like proteins have become successful biologics developed for cancer treatment, passive immunity against infection, addiction, and autoimmune diseases.
Kevin O. Saunders
doaj   +1 more source

Vaccinia protein C16 blocks innate immune sensing of DNA by binding the Ku complex [PDF]

open access: yes, 2011
VACV gene C16L encodes a 37-kDa protein that is highly conserved in orthopoxviruses and functions as an immunomodulator. Intranasal infection of mice with a virus lacking C16L (vΔC16) induced less weight loss, fewer signs of illness and increased ...
Peters, Nicholas Edward   +1 more
core   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors

open access: yesmAbs
A critical attribute of therapeutic antibodies is their ability to engage with humoral or cellular effector mechanisms, and this depends on the ability of the Fc region to bind to complement (C1q) or Fc receptors.
Geoff Hale   +2 more
doaj   +1 more source

Nuclear receptor complement of the cnidarian Nematostella vectensis: phylogenetic relationships and developmental expression patterns

open access: yesBMC Evolutionary Biology, 2009
Background Nuclear receptors are a superfamily of metazoan transcription factors that regulate diverse developmental and physiological processes.
Tarrant Ann M, Reitzel Adam M
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]

open access: yes, 2009
The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core   +2 more sources

Home - About - Disclaimer - Privacy